Torrent Pharmaceuticals posted a steady set of numbers in the fourth quarter, reinforcing confidence in its growth trajectory ...

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

With the stock's price at Rs 3222.50, Torrent Pharmaceuticals' performance reflects its position in the pharmaceutical sector.

The rally is being fuelled by solid quarterly results and a string of optimistic fiscal 2026 outlooks from leading drugmakers ...

Total revenue from operations grew 7.79% year on year (YoY) to Rs 2,959 crore in the quarter ended 31 March 2025. Profit ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

Torrent Pharmaceuticals reports strong revenue growth in key markets, posting a 15.4% rise in net profit for FY 2024-25.

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Torrent Pharmaceuticals reported steady growth in Q4 with an 11% rise in profit and strong margins. The board recommended a ...

The drugmaker, part of the ₹45,000-crore Torrent Group, also announced a leadership transition. As part of a long-term ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Indian drugmaker Torrent Pharmaceuticals missed fourth-quarter profit and revenue estimates on Tuesday, hurt by currency depreciation in Brazil, its top overseas market by revenue.